UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

~~Form~~FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER ~~PURSUANT TO RULE 13a-16 OR 15d-16~~

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of ~~December~~November ~~2024~~2025

Commission File Number: 333-269315

CORDYCEPS SUNSHINE BIOTECH HOLDINGS CO., LTD.

(Translation of registrant’s name into English)

6th Fl., No. 15, Lane 548, Ruiguang Road,
Neihu District, Taipei City, Taiwan

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form ~~40F.~~40-F:

Form 20-F ☒ Form 40-F ☐

Changes in Company’s Certifying Accountant.

(1) Previous Independent Registered Public Accounting Firm

(i) OnEffective ~~December~~on 2November 10, ~~2024~~2025, Cordyceps Sunshine Biotech Holdings Co., Ltd. (the “Company”) ~~notified~~terminated ~~its~~KCCW ~~independent~~Accountancy ~~registered~~Corp. ~~public accounting firm, TPS Thayer, LLC its decision to dismiss TPS Thayer, LLC~~ as the Company’s ~~auditor~~independent registered public accounting firm.

(ii) The ~~decision~~reports toof ~~change~~KCCW Accountancy Corp. on consolidated balance sheets of the ~~independent~~Company ~~registered~~for ~~public~~the ~~accounting~~fiscal ~~firm~~year ~~was~~ended ~~approved~~December by31, 2024 and 2023 and the ~~Board~~consolidated statements of ~~Directors~~operations and comprehensive loss, consolidated statements of changes in shareholders’ equity (deficit), and consolidated statements of cash flows for the ~~Company~~fiscal years ended December 31, 2024, and 2023, did not contain an adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles.

(iii) ~~During~~The ~~March~~decision ~~18,~~to ~~2024~~change ~~and through December 2, 2024,~~ the ~~date~~independent ofregistered ~~dismissal,~~public ~~(a) there were no disagreements with TPS Thayer, LLC on any matter of~~ accounting ~~principles~~firm orwas ~~practices,~~approved ~~financial~~by ~~statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to~~ the ~~satisfaction~~Board of ~~TPS~~Directors ~~Thayer,~~of ~~LLC, would have caused it to make reference thereto in its reports on~~ the ~~financial statements for such years and (b) there were no “reportable events” as described in Item 304(a)(1)(v) of Regulation S-K~~Company.

(iv) OnDuring the Company’s most recent fiscal year ended December 531, 2024 and through November 10, 2025, the ~~Company~~date ~~provided~~of ~~TPS Thayer~~dismissal, ~~LLC~~(a) there were no disagreements with aKCCW ~~copy~~Accountancy Corp. on any matter of ~~this~~accounting ~~Current~~principles ~~Report~~or ~~and~~practices, ~~has~~financial ~~requested~~statement ~~that~~disclosure, itor ~~furnish~~auditing ~~the~~scope ~~Company~~or ~~with~~procedure, awhich ~~letter~~disagreements, ~~addressed~~if not resolved to the ~~U.S.~~satisfaction ~~Securities~~of ~~and~~KCCW ~~Exchange~~Accountancy ~~Commission~~Corp., ~~stating~~would ~~whether~~have caused it ~~agrees~~to ~~with~~make ~~the~~reference ~~above~~thereto ~~statements.~~in Aits ~~copy~~reports ofon the financial statements for such ~~letter~~year isand ~~attached~~(b) asthere ~~Exhibit~~were ~~16.1~~no to“reportable ~~this~~events” ~~Report~~as ofdescribed ~~Foreign~~in ~~Private~~Item ~~Issuer~~304(a)(1)(v) onof ~~Form~~Regulation 6S-K.

(v)

The Company provided KCCW Accountancy Corp. with a copy of this Current Report and has requested that it furnish the Company with a letter addressed to the U.S. Securities and Exchange Commission stating whether it agrees with the above statements. A copy of such letter is attached as Exhibit 16.1 to this Report of Foreign Private Issuer on Form 6-K.

(2) New Independent Registered Public Accounting Firm

On ~~December~~November 215, ~~2024~~2025, the Board of Directors of the Company approved and ratified the appointment of ~~KCCW~~YCM ~~Accountancy~~CPA ~~Corp~~INC. as its new independent registered public accounting firm to audit the Company’s financial statements, effective November 15, 2025. During the two most recent fiscal years ended December 31, ~~2023~~2024 and ~~2022~~2023 and any subsequent interim periods through the date hereof prior to the engagement of ~~KCCW~~YCM ~~Accountancy~~CPA ~~Corp~~INC., neither the Company, nor someone on its behalf, has consulted ~~KCCW~~YCM ~~Accountancy~~CPA ~~Corp~~INC. regarding:

(i)

either: the application of accounting principles to a specified transaction, either completed or proposed; or the type of audit opinion that might be rendered on the Company’s consolidated financial statements, and either a written report was provided to the Company or oral advice was provided that the new independent registered public accounting firm concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue; or

(ii)

any matter that was either the subject of a disagreement as defined in paragraph 304(a)(1)(iv) of Regulation S-K or a reportable event as described in paragraph 304(a)(1)(v) of Regulation S-K.

Exhibit Index

Exhibit No.		Description
16.1		Letter from ~~TPS~~KCCW ~~Thayer,~~Accountancy ~~LLC~~Corp. addressed to the U.S. Securities and Exchange Commission

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: December 6, 2024	CORDYCEPS SUNSHINE BIOTECH HOLDINGS CO., LTD.
	CORDYCEPS SUNSHINE BIOTECH HOLDINGS CO., LTD.
	By:	/s/ Szu Hao Huang
Date: November 25, 2025	By:	/s/ Szu Hao Huang
	Name:	Szu Hao Huang
	Title:	~~Director~~Chief Executive Officer, Chief ~~Executive~~Financial Officer, Director
		Chief Financial Officer

Filing Compare · Cordyceps Sunshine Biotech Holdings Co., Ltd.